Rewiew Article
Hindawi Publishing Corporation, Tuberculosis Research and Treatment; Volume 2011, Article ID 712736, 6 pages, doi:10.1155/2011/712736
Clinical Infectious Diseases, cix705, https://doi.org/10.1093/cid/cix705
Cholera is an acute diarrhoeal disease caused by the ingestion of food or water contaminated with the bacterium V.
cholerae. It has a short incubation period of a few hours to 5 days. It is endemic in some countries, frequently
showing seasonal variations in the number of reported cases. Cholera a...lso has the potential to cause explosive
outbreaks which may be localized or may expand to large geographic areas
more
It is recommended that egg based quadrivalent vaccines for use in the 2019-2020 northern hemisphere influenza season contain the following:
an A/Brisbane/02/2018 (H1N1)pdm09-like virus;
an A(H3N2) virus to be announced on 21 March 2019*;
a B/Colorado/06/2017-like virus (B/Victoria/...2/87 lineage); and
a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
It is recommended that the influenza B virus component of trivalent vaccines for use in the 2019-2020 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.
* In light of recent changes in the proportions of genetically and antigenically diverse A(H3N2) viruses, the recommendation for the A(H3N2) component has been postponed.
more
Global Campaign Against Epilepsy
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.
Topics in Antiviral Medicine Volume 25 Issue 2 May/June 2017
Updated on 6 APRIL 2020
There are serious concerns that the situation might escalate in the next weeks modelling the epi curve of other regions. The interlinkages between human mobility and the current pandemic of COVID-19 are well established, and while international flights have been suspended i...n the region, the porous borders on land and water crossings remain difficult to control.
more
The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is ...important. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges. No further updates to the previous existing recommendations were made in this latest version.
This updated (fifth) version contains 16 new recommendations for the rehabilitation of adults with post COVID-19 condition (see Chapter 24)
This updated (fourth) version contains three new recommendations regarding hospitalized patients with severe or critical COVID-19
more
The COVID-19 pandemic’s immediate costs, measured in lives lost and damaged, have been appalling and continue to rise. In addition, its effects on individuals’ livelihoods and economies around the world have been deep and are likely to be long lasting. While saving lives was the near-exclusive f...ocus during the first phase of the crisis, governments are now trying to strike a delicate balance between preventing further economic damage by reopening parts of their economies, while managing the obvious health risks of doing so.
In the international mobility and migration arenas—policy areas enormously affected by the health and economic effects of the pandemic—this reflection considers both how these fields have fared thus far and the challenges that lay ahead
more
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological
situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171
countries across all six WHO Regions and was rapidly re...placing Delta worldwide – was considered Omicron has a substantial growth advantage, higher secondary attack rates and a higher observed reproduction number than Delta.
There is now significant evidence that immune evasion contributes to the rapid spread of Omicron. Other factors may be a shorter
serial interval (by about 0.8 to 1.2 days compared to Delta) and potential increased intrinsic transmission fitness . There is
growing evidence that with Omicron, there is lower vaccine effectiveness (VE) against infection and symptomatic disease soon after vaccination compared to Delta. There is also evidence of accelerated waning of VE over time of the primary series against infection and symptomatic disease for the studied vaccines. Further studies are required to better understand the drivers of transmission and declining incidence in various settings. These factors include the intrinsic transmission fitness properties of the virus, degree of immune evasion, vaccination coverage and level of vaccine-derived and post-infection immunity, levels of social mixing and degree of application of public health and social measures (PHSM).
more